Skip to content
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact

Latest Press Release

Albert Labs Appoints Mackie Research As Lead Agent For Private Placement Of Proceeds Up To $4 Million Pre-RTO

 

Read more

Albert Labs -

Accelerated access to safe and effective psychedelic-assisted therapy.

1906 to 2020, from Albert Hofmann's birth to ours >>

Rethinking the clinical trial paradigm.

We’re different. We focus on Real World Data to meet immediate, unmet, clinical needs.

Continued success shows psychedelic medicine is a potential game-changer, but patients could be waiting 5+ years for new treatments to come to market.

Real World Evidence Explained

Portable, scalable strategy for revenue growth.

Albert Labs is a catalyst leading a collaboration with academic institutions, hospital networks and existing reimbursement mechanisms.

  • Leveraging existing clinic & research infrastructure.
  • Academic partnerships drive next gen psychedelic R&D.
  • Preidenitfied, accessible patient pools.
  • Proprietary Real World Data to gain early reimbursement.
  • In-house lab results in formulation & delivery IP.

Alberts Labs’ mission to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Learn more

Let us tell you more.

We will email you to start the conversation.

Meet the experts delivering real world evidence to enable access to psychedelic medicine to those most in need.

Albert has the people, expertise, and connections to build these unique protocols. Albert's team have delivered successful trials across multiple compounds, conditions and jurisdictions within Europe.
Meet the team
"There is an opportunity here to provide something of real value to patients who are truly suffering."
Dr. Michael Raymont
Dr. Michael RaymontDirector, CEO
"The average clinical trial takes 6-12 years and costs over half a billion dollars we can't let patients wait that long."
Graeme McFarlane
Graeme McFarlaneChief Commercial Officer
Previous
Next

UK focus, supplied by Canadian R&D facility.

Application has been made for a dealers license allowing Albert Labs to test, possess, import and export. Proprietary bioreactor cultivation, extraction and formulation protocols using Industry-leading technology.

Learn more

Faster

Through Real World Evidence we can accelerate innovation and access to patients suffering now and generate revenue along the way. 

Focused

Patient focused data and physician usage experience will help unlock reimbursement pathways faster bringing science and continuity to those in need.

Credible

Real World Evidence is quickly becoming the acceptable protocol to assess innovative formulations as effective. Regarded by regulators and policymakers.

Insights

Larger data sets from a breadth of representative patient populations. Real-world insights enable us to develop unique formulations and delivery

<<1906 from Albert Hofmann's birth to ours
Standing on the shoulders of the giants that went before.

We are driven to develop the vision of those that revealed the true power of psychedelics as medicines.

Learn the history

“The outcome of these experiments took place in the framework of systematic pharmaceutical, chemical research.”

- Albert Hofmann, 1938 Novartis Labs (Sandoz) , Basel Switzerland.

Who is Albert?

Albert Hofmann pioneered the discovery  and development of psychedelic therapies including LSD & Psilocybin, understanding  their therapeutic value first hand.

Meet Albert Hofmann

Let us tell you more.

We will email you to start the conversation.

accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs.

Facebook
Twitter
Linkedin
Youtube
Envelope
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
Menu
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact
Menu
  • About
  • Team
  • Clinical Studies
  • Investing
  • Press
  • Contact

© 2021 Albert Labs. All Rights Reserved

Canada – 6996, Merritt Ave, Burnaby, BC, V5J 4R6 | United kingdom – 21 Marylebone High St, Unit 6, Marylebone, London W1U 4PE

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok